Spin-offs

In 2002, our lab Co-founded of Ablynx. Ablynx is engaged in the development of proprietary therapeutic Nanobodies. The company has approximately 40 proprietary and partnered programs in therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. In 2018, Ablynx was acquired by Sanofi (France) for €3.9B.

In 2013, we Co-founded AgroSafve, now Biotalys. Biotalys employs a Nb-based platform to develop biopesticides for the control of pests and diseases on crops and harvested products. In 2019, Agrosafe secured a €33M series C round to support the launch of its first product in the US.
 

In 2015, we founded Confo Therapeutics. Confo Therapeutics employs proprietary Nanobody technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. In 2019, the company raised 37M€ to secure its growth.